StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Lenvima (lenvatinib by Quarter

Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Lenvima (lenvatinib: 6.0% in Q2 2026, up 1.0 pts from a year earlier.

Latest, Q2 2026
6.0%
Period ended Jun 30, 2026
Change on a year earlier
+1.0 pts
5.0% in Q2 2025
History
23 quarters
Since Q4 2019
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Lenvima (2) | 256 | 283 | 539 | 258 | 265 | 523 | 258 | 272 | 1,053 | 7 | 6 | 3 | 2”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20266.0%+1.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20256.0%-8.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20252.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20255.0%+1.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q4 2024Dec 31, 202414.0%+9.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 20244.0%-2.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202410.0%+5.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 20235.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202330.0%+19.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 20236.0%-27.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 20235.0%-72.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 202211.0%-19.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202233.0%+18.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202277.0%+78.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202131.0%+5.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202130.0%+1.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗

Cite this data

StockData. (2026). Merck Lenvima (lenvatinib (%), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.